Concepedia

Mirjam de With

MD

7

Publications

253

Citations

7

H-Index

2018

Active since

Affiliations

Erasmus MC Cancer Institute(Current)

Erasmus MC

Leiden University Medical Center

Erasmus University Rotterdam

Mirjam de With is an author at Erasmus MC Cancer Institute specializing in drug safety, pharmacogenomics, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2018–2023

7

Publications

7

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe

Mirjam de With, A. Sadlon, Erika Cecchin et al. · ESMO Open · 2023 · 59 citations · Full text

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study

Mirjam de With, Jonathan E. Knikman, Femke M. de Man et al. · Clinical Pharmacology & Therapeutics · 2022 · 54 citations · Full text

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

Emma C. Hulshof, Mirjam de With, Femke M. de Man et al. · European Journal of Cancer · 2022 · 48 citations · Full text

, , +5

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy

Mirjam de With, Daan P. Hurkmans, Esther Oomen‐de Hoop et al. · Cancers · 2021 · 40 citations · Full text

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study

Femke M. de Man, Koen G. A. M. Hussaarts, Mirjam de With et al. · Clinical Pharmacology & Therapeutics · 2018 · 21 citations · Full text

Rows per page

1–5 of 7